No Picture
News

UPDATED: Gilead leases partner rights to TIGIT, PD-1 in a $2B deal with Arcus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash f… […]

No Picture
News

VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions

Novel Cocrystal Form of AV-101 Administered with Probenecid May Have Superior Delivery, an Enhanced Therapeutic Profile and Additional Intellectual Property Protection

SOUTH SAN FRANCISCO, Calif., May 27, 2020 /PRNewswire/ — VistaGen Therapeutics (… […]

No Picture
News

In latest cancer deal, Bristol Myers Squibb’s new BD chief bets $80M in search for more targets like PARP

Elizabeth Mily, the new chief of the strategy and business development group at Bristol Myers Squibb, has struck her first high-profile collaboration since succeeding Paul Biondi. In putting down $80 million upfront, she’s also signaling where the phar… […]